View more in
Health

Investigators start pivotal subretinal gene therapy trial

ophthalmologytimes.com
 2021-06-11

Cover picture for the articleRGX-314 eyed by investigators as a therapeutic option for exudative AMD. RGX-314 subretinal gene therapy (REGENXBIO Inc) is being tested in the first pivotal gene therapy trial for exudative age-related macular degeneration (AMD). Interim results indicate the treatment is generally well tolerated with stable to improved visual acuity (VA) and...

www.ophthalmologytimes.com

Comments / 0

Comments / 0